Nothing new on Amicus Therapeuticsin the last three months. We read the news on it every day, write up anything that matters once a week, and tell you sooner if something can't wait. A quiet stretch is normal and is not a signal by itself.
Amicus Therapeutics analyst price targets
Average target$14.86+3%vs $14.49 today
Avg price
Low $13High $19
Buy24 analysts
1Bearish
7Neutral
16Bullish
FirmRatingPrice TargetDate
Jefferies
Hold
$14.50
1/22/2026
Cantor Fitzgerald
Neutral
$14.50
12/19/2025
Needham
Hold
$14
9/18/2025
Bank of America Securities
—
$15
10/17/2024
Guggenheim
Buy
$13
5/14/2024
Morgan Stanley
Overweight
$19
5/9/2024
Morgan Stanley
Overweight
$20
12/19/2023
Goldman Sachs
Neutral
$14
5/10/2021
Amicus Therapeutics earnings
The company has a history of small beats, suggesting management is conservative with its targets and consistently clears the bar.
Earnings history
EstimateBeatMiss
Amicus Therapeutics past earnings results
Expected
Actual
Surprise
EPS
$0.07
$0.01
-86.0%
Revenue
$181M
$185M
+2.6%
Metrics we are tracking
Metric
Expectations
Status
Pompe Franchise Growth
Growing above 40% YoY annually through 2027
60% YoY for FY2025
Fabry Market Share
Maintaining current share above 40% of amenable patients
~40% of amenable patients in 2025
FCF Margin
Staying positive and expanding toward 10% of revenue
5% in FY2025 ($33M on $634M rev)
Patient Compliance
Retention rates staying above 90% annually
>90% as of Q4 2025
Stay on top of Amicus Therapeutics
Follow Amicus Therapeutics to get the latest and most important updates.